Skip to content

Study · Randomized controlled trial · n = 40 · 2024

2 results

Clinical trial: The effectiveness of long-acting somatostatin analogue for output reduction of high-output intestinal fistula or small bowel enterostomy. A randomised controlled trial.

Timmer AS, de Vries F, Gans SL, Zwanenburg PR, Bemelman WA, Dijkgraaf MGW, Dijkstra G, van der Heide F, Haveman JW, Serlie MJ, Boermeester MA

Alimentary pharmacology & therapeutics11 Jul 2024Cited by 3 (Europe PMC)

PMID38993030 (opens in a new tab)DOI10.1111/apt.18166 (opens in a new tab)PepBankPUB-38993030
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In high-output fistula or enterostomy patients, 9/20 responded with added lanreotide versus 2/20 with standard treatment alone (p = 0.013).

    In plain wordsIn high-output fistula or enterostomy patients, 9/20 responded with added lanreotide versus 2/20 with standard treatment alone.

    Peptide
    Lanreotide
    Outcome
    IncreaseOutput reduction responders
    Study

    n = 40

    Comparator
    standard treatment alone
    Analysis
    Primary
    Outcome group
    Intestinal Output · Gastrointestinal
    Studied dose
    120 mg every 4 weeks · subcutaneousAs given in this study (human).

    Measurements

    Responders (output reduction >=25%)
    9 patients
    lanreotide plus standard treatment, of 20
    Responders (output reduction >=25%)
    2 patients
    standard treatment alone, of 20
    P value
    0.013 p
    between groups

    Source sentences

    Summary
    There were 9/20 responders in the intervention group and 2/20 in the control group (p = 0.013).
    4 context sentences
    Summary · context
    This was an open-label, multicentre, randomised controlled trial.
    Summary · context
    Adult patients with a high-output intestinal fistula (>500 mL/24 h) or small bowel enterostomy (>1500 mL/24 h) more than 4 weeks post-surgery and receiving standard medical treatment (dietary- and fluid restriction, PPI, loperamide and codeine) for at least 2 weeks were eligible for inclusion.
    Summary · context
    We randomised patients 1:1 between continuing standard treatment (control), and subcutaneous lanreotide 120 mg every 4 weeks with standard treatment.
    Summary · context
    The primary outcome was the number of responders, with response defined as an output reduction of ≥25%, 8 weeks after randomisation.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In high-output fistula or enterostomy patients, output changed by -26% (IQR -4 to -38) with lanreotide versus +4% (20 to -13) with control (p = 0.004).

    In plain wordsIn high-output fistula or enterostomy patients, output fell 26% with added lanreotide versus a 4% increase with standard treatment alone.

    Peptide
    Lanreotide
    Outcome
    DecreaseProportional intestinal output change
    Study

    n = 40

    Comparator
    standard treatment alone
    Outcome group
    Intestinal Output · Gastrointestinal
    Studied dose
    120 mg every 4 weeks · subcutaneousAs given in this study (human).

    Measurements

    Proportional output change
    −26%
    lanreotide plus standard treatment
    IQR of proportional output change
    −38 to −4%
    lanreotide plus standard treatment
    Proportional output change
    4%
    standard treatment alone
    IQR of proportional output change
    −13 to 20%
    standard treatment alone
    P value
    0.004 p
    between groups

    Source sentences

    Summary
    The proportional output reduction was -26% (IQR -4 to -38) in the intervention group, compared to an increase of 4% (IQR 20 to -13) in the control group (p = 0.004).
    4 context sentences
    Summary · context
    This was an open-label, multicentre, randomised controlled trial.
    Summary · context
    Adult patients with a high-output intestinal fistula (>500 mL/24 h) or small bowel enterostomy (>1500 mL/24 h) more than 4 weeks post-surgery and receiving standard medical treatment (dietary- and fluid restriction, PPI, loperamide and codeine) for at least 2 weeks were eligible for inclusion.
    Summary · context
    We randomised patients 1:1 between continuing standard treatment (control), and subcutaneous lanreotide 120 mg every 4 weeks with standard treatment.
    Summary · context
    The primary outcome was the number of responders, with response defined as an output reduction of ≥25%, 8 weeks after randomisation.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.